atopic dermatitis

News

Sanofi's bispecific lunsekimig has mixed readouts in phase 2

Sanofi's IL-13 and TSLP-targeting bispecific lunsekimig wins two, loses one, in readouts from its midstage clinical trials programme.

News

Cancer risk scuppers Kyowa Kirin's autoimmune disease drug

Kyowa Kirin has terminated all clinical trials of its anti-OX40L antibody rocatinlimab, after cases of cancer were seen in patients taking the drug.

News

MSD and Mayo Clinic team up on AI drug discovery

MSD has signed an industry-first deal with the Mayo Clinic that will allow it to use the health system's genomic and clinical data for drug discovery.

News

Sanofi plans amlitelimab dermatitis filing after new readout

Sanofi has said it will press ahead with regulatory filings for atopic dermatitis candidate amlitelimab, despite mixed data in phase 3.

News

J&J abandons trial of atopic dermatitis drug

J&J has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis, acquired in 2024 in a $1.25bn takeover deal.

News

Sanofi slumps despite positive eczema drug readout

Shares in Sanofi have fallen after it reported data from a phase 3 trial of atopic dermatitis drug amlitelimab – even though it met all objectives.

Sanofi's bispecific lunsekimig has mixed readouts in phase 2

Cancer risk scuppers Kyowa Kirin's autoimmune disease drug

MSD and Mayo Clinic team up on AI drug discovery

Sanofi plans amlitelimab dermatitis filing after new readout

J&J abandons trial of atopic dermatitis drug

Sanofi slumps despite positive eczema drug readout

AbbVie tries a new approach in 340B programme battle

Using AI-driven synthetic personas to take your insights fur...

atopic dermatitis

Editor's Picks